OncoMatch/Clinical Trials/NCT06810609
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Is NCT06810609 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Immunotherapy for lung cancer non-small cell cancer (nsclc).
Treatment: Immunotherapy — The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Disease stage
Required: Stage IIIA, IIIB (IASLC/UICC 8)
Excluded: Stage N3 TUMORS (IASLC/UICC 8)
Selected patients with NSCLC stage IIIA/B: IIIA: one or more lymph node levels involved at EBUS/mediastinoscopy T1/T2 N2. IIIB: one or more lymph node levels involved at EBUS/mediastinoscopy T3/T4 N2.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: mediastinal irradiation
Prior treatments including prior mediastinal irradiation
Cannot have received: anti-PD-1 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Cannot have received: anti-PD-L1 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Cannot have received: anti-CTLA-4 therapy
Exception: Permitted if no permanent discontinuation for toxicity, all AEs resolved to baseline, no ≥ Grade 3 immune-related AE or immune-related neurologic/ocular AE of any grade, no additional immunosuppression other than corticosteroids, no recurrence of AE if re-challenged, not currently requiring >10 mg prednisone or equivalent per day. Endocrine AE ≤ Grade 2 allowed if stably maintained and asymptomatic.
Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L
Kidney function
Measured or calculated creatinine clearance ≥ 60 mL/min
Liver function
Serum bilirubin ≤ 1.5 × institutional ULN (except Gilbert's syndrome); ALT/AST ≤ 2.5 × institutional ULN
Cardiac function
Stable cardiac function (no MI within 6 months, no heart failure NYHA III-IV)
Adequate normal organ and bone marrow function as defined below: Hemoglobin ≥ 9.0 g/dL. ANC ≥ 1.5 × 10^9/L. Platelet count ≥ 100 × 10^9/L. Serum bilirubin ≤ 1.5 × institutional ULN. ALT/AST ≤ 2.5 × institutional ULN. Creatinine clearance ≥ 60 mL/min. Stable cardiac function (no MI within 6 months, no heart failure NYHA III-IV).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06810609 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIA or IIIB is required.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages